Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: Continued experience of a phase I trial in rectal cancer patients [18]

Christopher G. Willett; Yves Boucher; Dan G. Duda; Emmanuelle Di Tomaso; Lance L. Munn; Ricky T. Tong; Sergey V. Kozin; Lucine Petit; Rakesh K. Jain; Daniel C. Chung; Dushyant V. Sahani; Sanjeeva P. Kalva; Kenneth S. Cohen; David T. Scadden; Alan J. Fischman; Jeffrey W. Clark; David P. Ryan; Andrew X. Zhu; Lawrence S. Blaszkowsky; Paul C. Shellito; Mari Mino-Kenudson; Gregory Y. Lauwers

doi:10.1200/JCO.2005.02.5635

Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: Continued experience of a phase I trial in rectal cancer patients [18]

Christopher G. Willett, Yves Boucher, Dan G. Duda, Emmanuelle Di Tomaso, Lance L. Munn, Ricky T. Tong, Sergey V. Kozin, Lucine Petit, Rakesh K. Jain, Daniel C. Chung, Dushyant V. Sahani, Sanjeeva P. Kalva, Kenneth S. Cohen, David T. Scadden, Alan J. Fischman, Jeffrey W. Clark, David P. Ryan, Andrew X. Zhu, Lawrence S. Blaszkowsky, Paul C. ShellitoMari Mino-Kenudson, Gregory Y. Lauwers

Research output: Contribution to journal › Letter › peer-review

383 Scopus citations

Original language	English (US)
Pages (from-to)	8136-8139
Number of pages	4
Journal	Journal of Clinical Oncology
Volume	23
Issue number	31
DOIs	https://doi.org/10.1200/JCO.2005.02.5635
State	Published - 2005

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1200/JCO.2005.02.5635

Cite this

Willett, C. G., Boucher, Y., Duda, D. G., Di Tomaso, E., Munn, L. L., Tong, R. T., Kozin, S. V., Petit, L., Jain, R. K., Chung, D. C., Sahani, D. V., Kalva, S. P., Cohen, K. S., Scadden, D. T., Fischman, A. J., Clark, J. W., Ryan, D. P., Zhu, A. X., Blaszkowsky, L. S., ... Lauwers, G. Y. (2005). Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: Continued experience of a phase I trial in rectal cancer patients [18]. Journal of Clinical Oncology, 23(31), 8136-8139. https://doi.org/10.1200/JCO.2005.02.5635

Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: Continued experience of a phase I trial in rectal cancer patients [18]. / Willett, Christopher G.; Boucher, Yves; Duda, Dan G. et al.
In: Journal of Clinical Oncology, Vol. 23, No. 31, 2005, p. 8136-8139.

Research output: Contribution to journal › Letter › peer-review

Willett, CG, Boucher, Y, Duda, DG, Di Tomaso, E, Munn, LL, Tong, RT, Kozin, SV, Petit, L, Jain, RK, Chung, DC, Sahani, DV, Kalva, SP, Cohen, KS, Scadden, DT, Fischman, AJ, Clark, JW, Ryan, DP, Zhu, AX, Blaszkowsky, LS, Shellito, PC, Mino-Kenudson, M & Lauwers, GY 2005, 'Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: Continued experience of a phase I trial in rectal cancer patients [18]', Journal of Clinical Oncology, vol. 23, no. 31, pp. 8136-8139. https://doi.org/10.1200/JCO.2005.02.5635

@article{c416e5039e8b4ebda033a18fd6ea1181,

title = "Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: Continued experience of a phase I trial in rectal cancer patients [18]",

author = "Willett, \{Christopher G.\} and Yves Boucher and Duda, \{Dan G.\} and \{Di Tomaso\}, Emmanuelle and Munn, \{Lance L.\} and Tong, \{Ricky T.\} and Kozin, \{Sergey V.\} and Lucine Petit and Jain, \{Rakesh K.\} and Chung, \{Daniel C.\} and Sahani, \{Dushyant V.\} and Kalva, \{Sanjeeva P.\} and Cohen, \{Kenneth S.\} and Scadden, \{David T.\} and Fischman, \{Alan J.\} and Clark, \{Jeffrey W.\} and Ryan, \{David P.\} and Zhu, \{Andrew X.\} and Blaszkowsky, \{Lawrence S.\} and Shellito, \{Paul C.\} and Mari Mino-Kenudson and Lauwers, \{Gregory Y.\}",

year = "2005",

doi = "10.1200/JCO.2005.02.5635",

language = "English (US)",

volume = "23",

pages = "8136--8139",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "Lippincott Williams and Wilkins",

number = "31",

}

TY - JOUR

T1 - Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy

T2 - Continued experience of a phase I trial in rectal cancer patients [18]

AU - Willett, Christopher G.

AU - Boucher, Yves

AU - Duda, Dan G.

AU - Di Tomaso, Emmanuelle

AU - Munn, Lance L.

AU - Tong, Ricky T.

AU - Kozin, Sergey V.

AU - Petit, Lucine

AU - Jain, Rakesh K.

AU - Chung, Daniel C.

AU - Sahani, Dushyant V.

AU - Kalva, Sanjeeva P.

AU - Cohen, Kenneth S.

AU - Scadden, David T.

AU - Fischman, Alan J.

AU - Clark, Jeffrey W.

AU - Ryan, David P.

AU - Zhu, Andrew X.

AU - Blaszkowsky, Lawrence S.

AU - Shellito, Paul C.

AU - Mino-Kenudson, Mari

AU - Lauwers, Gregory Y.

PY - 2005

Y1 - 2005

UR - https://www.scopus.com/pages/publications/30944452436

UR - https://www.scopus.com/inward/citedby.url?scp=30944452436&partnerID=8YFLogxK

U2 - 10.1200/JCO.2005.02.5635

DO - 10.1200/JCO.2005.02.5635

M3 - Letter

C2 - 16258121

AN - SCOPUS:30944452436

SN - 0732-183X

VL - 23

SP - 8136

EP - 8139

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 31

ER -

Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: Continued experience of a phase I trial in rectal cancer patients [18]

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this